If you are trying to decide between Mounjaro and Wegovy for weight loss, you are asking exactly the right question — and you are not alone. Both are once-weekly injectable GLP-1 medications that have transformed the weight loss landscape in the UK, but they contain different active ingredients, work through slightly different mechanisms, and produce different average weight loss outcomes in clinical trials. Mounjaro (tirzepatide) is a dual GIP/GLP-1 receptor agonist — the first of its kind — while Wegovy (semaglutide) is a GLP-1 receptor agonist with a well-established clinical record and, notably, now also available as an oral tablet for patients who prefer not to inject. For most patients, the choice between the two comes down to a combination of clinical efficacy, personal preference, medical history, and the guidance of a qualified prescriber who can assess which is most appropriate for their individual circumstances. At The Care Pharmacy, our prescribing team helps patients across the UK navigate exactly this decision through a straightforward, confidential online consultation.
Our prescribing team is here to help — get in touch with any questions, or complete our online consultation to find out which weight loss treatment is right for you.
Quick Answer
Mounjaro (tirzepatide) and Wegovy (semaglutide) are both once-weekly injectable prescription weight loss medications available in the UK, but Mounjaro is generally the more effective of the two based on current clinical trial data. Mounjaro is a dual GIP/GLP-1 receptor agonist — it activates two hormone receptors simultaneously — while Wegovy activates only the GLP-1 receptor, which accounts for the difference in average weight loss outcomes. Clinical trials show average weight loss of up to 20.9% of body weight with Mounjaro at the highest dose, compared to 14.9% with Wegovy at its maintenance dose. Wegovy has the advantage of a longer clinical track record and, uniquely, is now also available as an oral tablet — the first GLP-1 medication in pill form to receive MHRA approval in the UK — offering patients who prefer not to inject an alternative delivery route. The most appropriate choice for any individual patient depends on their BMI, medical history, lifestyle, and clinical assessment — factors best evaluated through a confidential consultation with a qualified prescriber.
Mounjaro (tirzepatide) is a once-weekly subcutaneous injection developed by Eli Lilly and approved by the MHRA for weight management in adults in the UK. It is the first medication in a new class called dual GIP/GLP-1 receptor agonists — meaning it activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor simultaneously, producing a more comprehensive hormonal response than single-receptor GLP-1 medications.
Mounjaro was originally developed for the treatment of type 2 diabetes (under the brand name Mounjaro for diabetes, at lower doses) before its weight management indication was established through the SURMOUNT clinical trial programme, which demonstrated remarkable weight loss results that exceeded anything previously seen with a non-surgical treatment.
Key facts about Mounjaro:
Wegovy (semaglutide 2.4mg) is a once-weekly GLP-1 receptor agonist developed by Novo Nordisk. It is the higher-dose weight management formulation of semaglutide — the same active ingredient used in Ozempic (2mg) for type 2 diabetes management, but at a higher dose specifically licensed for weight loss. Wegovy has an established clinical track record through the STEP trial programme and has been available longer in the UK than Mounjaro, giving it a broader base of real-world evidence.
One of Wegovy’s most significant recent developments is the approval of an oral tablet formulation — making it the first GLP-1 medication available as a pill in the UK. This is a meaningful option for patients who are uncomfortable with self-injection, have a needle phobia, or simply prefer the convenience of a daily tablet over a weekly injection.
Key facts about Wegovy:
The most clinically significant difference between Mounjaro and Wegovy lies in their mechanisms of action — specifically, the number of hormone receptors they activate.
Wegovy (semaglutide) — single GLP-1 receptor agonist
Wegovy mimics the action of GLP-1 (glucagon-like peptide-1), a hormone naturally released by the gut after eating. By activating GLP-1 receptors throughout the body, it produces several effects relevant to weight loss:
Mounjaro (tirzepatide) — dual GIP and GLP-1 receptor agonist
Mounjaro activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. GIP is another gut hormone that plays a role in fat storage, insulin regulation, and energy balance. The addition of GIP receptor activation to the GLP-1 mechanism is thought to produce a synergistic effect — amplifying the appetite suppression, metabolic improvements, and weight loss beyond what GLP-1 agonism alone can achieve. This dual mechanism is the primary explanation for Mounjaro’s superior average weight loss outcomes in head-to-head and comparative clinical data.
In practical terms, both medications reduce appetite, slow gastric emptying, and produce sustained caloric deficit over time — but Mounjaro does so through a broader and more potent hormonal pathway, which translates into greater average weight loss across patient populations.
Based on published clinical trial data, Mounjaro produces greater average weight loss than Wegovy. This is not a close comparison — the difference in outcomes at the highest doses is clinically meaningful.
Mounjaro clinical trial data (SURMOUNT-1):
Wegovy clinical trial data (STEP 1):
It is important to note that these trials were conducted separately, with different patient populations and protocols, so a direct head-to-head comparison must be interpreted with appropriate caution. Individual responses vary significantly — some patients achieve substantially more than the average on either medication, and some achieve less. The right medication for an individual patient is not always the one with the highest average trial result.
Reach out to our team today — get in touch to discuss which option is most likely to be effective for your specific presentation, or complete our online consultation to get started.
Both Mounjaro and Wegovy belong to the same broad pharmacological class — GLP-1 receptor agonists — and share a largely overlapping side effect profile. The most commonly reported side effects of both medications are gastrointestinal in nature and are most prominent during the dose escalation phase.
Common side effects of both medications:
Rare but serious side effects (both medications):
In terms of relative tolerability, the side effect profiles of Mounjaro and Wegovy are broadly similar. Some patients find one medication better tolerated than the other — individual response varies and this is worth discussing with your prescriber if tolerability is a primary concern.
Side effects are only part of the story. See what these medications can achieve in practice by watching one patient’s remarkable weight loss transformation below:
@thecarepharmacyuk💕 Shared with patient permission Every patient’s journey is unique, and we’re proud to support people in working towards their health and wellbeing goals.♬ Taylor Swift shining star – Laura Paixão
For most patients, the following considerations help to guide the choice between the two medications:
Mounjaro may be the more appropriate choice if:
Wegovy may be the more appropriate choice if:
The most reliable way to identify the right choice for your circumstances is through a clinical consultation that takes your full medical history, current medications, BMI, lifestyle, and personal preferences into account.
Every patient’s circumstances are different, but this comparison provides a useful starting point for understanding where the two treatments differ most significantly. The table below covers the clinical and practical factors most relevant to making that decision, summarised clearly for quick reference.
We hear the same questions about Mounjaro and Wegovy time and again. Here are the most common ones, answered clearly and directly:
Based on published clinical trial data, Mounjaro produces greater average weight loss than Wegovy at their respective highest doses — 20.9% of body weight versus 14.9%. This is attributable to Mounjaro’s dual GIP/GLP-1 mechanism, which activates an additional hormonal pathway that amplifies appetite suppression and metabolic effects beyond what GLP-1 agonism alone achieves.
Yes — switching from Wegovy to Mounjaro is clinically possible and is sometimes recommended for patients who have not achieved adequate weight loss on Wegovy or who wish to try the more potent option. The switch should always be managed under clinical supervision, as dose timing and escalation need to be carefully planned to minimise side effects during the transition.
The oral semaglutide tablet (Wegovy pill) contains the same active ingredient as the injection — semaglutide — though the bioavailability of oral semaglutide is lower than the injectable form, meaning the dose and absorption characteristics differ. Clinical trial data for the oral formulation is encouraging, though patients considering the tablet over the injection should discuss the relative efficacy expectations with their prescriber.
Both medications share a broadly similar GI-dominated side effect profile, with nausea, vomiting, and digestive discomfort most common during dose escalation. Individual tolerability varies significantly between patients — some find one medication better tolerated than the other — and if side effects are a primary concern, this is an important discussion to have with your prescriber before starting either treatment.
Both medications are available on the NHS in specific circumstances through specialist weight management services, though access is subject to eligibility criteria and local commissioning decisions that vary across England. For patients who do not qualify for NHS access or who face long waiting times, both are available as private prescriptions through a GPhC-registered online pharmacy following a clinical consultation.
The most reliable way to identify the right treatment is through a clinical consultation that takes your full medical history, current medications, BMI, lifestyle preferences, and personal goals into account. Our prescribing team assesses every patient individually before making a recommendation — no single medication is right for every patient, and the best outcome comes from matching the treatment to the person.
Both Mounjaro and Wegovy are clinically transformative weight loss treatments that have changed what is achievable without surgery. Mounjaro currently leads on average efficacy — producing weight loss that rivals bariatric surgery for many patients — while Wegovy offers the unique advantage of an oral tablet option for those who prefer not to inject, alongside a longer established clinical track record. Neither is universally superior: the right choice depends on who you are, what your goals are, and what your clinical picture looks like.
At The Care Pharmacy, our pharmacist-led prescribing team is here to help you make that decision with confidence. Whether you are weighing up Mounjaro versus Wegovy for the first time or reconsidering your current treatment, our team will assess your full circumstances and recommend the most appropriate option — quickly, confidentially, and entirely online.
Take the first step today — reach out to our team with any questions, or complete our online consultation to find out which weight loss treatment is right for you.
This article was written by Pharmacy Mentor and clinically reviewed by Mohammed Ismail Lakhi, MPharm, MRPharm, Superintendent Pharmacist at The Care Pharmacy. Mohammed is registered with the General Pharmaceutical Council (GPhC registration number 2072815) and leads clinical governance across The Care Pharmacy’s weight management services.
Last reviewed: July 2026
Disclaimer: This article is for general information only and is not a substitute for individual medical advice. Always consult a qualified prescriber before starting any prescription weight loss treatment.
Medically reviewed by
Superintendent Pharmacist
The ability to buy semaglutide online has opened up access to effective weight loss treatment for thousands of patients across the UK. But with increased demand has come an increase in unregulated sellers, counterfeit products, and unsafe practices. Knowing how to navigate this landscape safely is essential before placing any order. Our prescribing team provides […]
Wegovy and Mounjaro are two popular injectable weight loss treatments that work by regulating appetite and supporting reduced calorie intake. As their use has grown in the UK, many patients want to understand the differences between them and whether one may be better suited to fasting during Ramadan. Regulated access to both treatments is available […]
Mounjaro has quickly become one of the most widely discussed medical weight loss treatments in the UK. Many patients experience noticeable appetite reduction and steady progress during the early stages of treatment. However, it is also very common to reach a point where weight loss slows down or temporarily stops, leading to frustration and the […]
If you are exploring prescription weight management options and wondering whether Xenical or a weight loss injectable is right for you, our clinical team can help. At The Care Pharmacy, we offer a range of medically approved weight loss treatments, including Xenical and several injectable options. The right choice depends on your health profile, weight […]
If you are researching whether weight loss injections are safe, you are likely looking beyond headlines and marketing claims. You want clarity on real risks, long-term safety, side effects, monitoring, and whether these treatments are appropriate for you personally. Weight loss injections such as GLP-1 based medications are now widely prescribed in the UK, both through […]
If you are experiencing mounjaro constipation, you are not alone. Constipation is a well recognised side effect of Mounjaro and other GLP-1 based weight loss treatments. For many people, it is mild and temporary. For others, it can be uncomfortable enough to affect daily life and confidence in continuing treatment. From the perspective of The […]
